Skip to main content
Clinical Trials/NCT04211766
NCT04211766CompletedNot Applicable

Diet and the Colonic Exfoliome: A Novel, Non-Invasive Approach to Testing Interventions in Humans

Fred Hutchinson Cancer Center2 sites in 1 country38 target enrollmentStarted: January 5, 2021Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
38
Locations
2
Primary Endpoint
Feasibility and Retention for a Trial With Daily Doses of 35 g of Fiber and 6.2 g of EPA +DHA (and Corresponding Comparators)

Study Overview

Brief Summary

This trial studies how fiber and fish oil supplements affect the metabolism and activities of colon cells in healthy individuals. Diet is an important risk factor for colorectal cancer, and several dietary components important in colorectal cancer prevention are modified by gut microbial metabolism. Giving fiber and fish oil supplements may inhibit the growth of gut cells and ultimately reduce risk of colorectal cancer.

Detailed Description

Participants are randomized to receive two dietary interventions in assigned random order. They either receive the dietary fiber supplement and fish oil supplement orally (PO) daily or they receive a fiber control and corn oil supplement daily for 30 days during the first intervention period. Then they enter a washout period for 60 days when they do not receive any treatment. After that they complete the second intervention period during which they receive the other intervention.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Primary Purpose
Prevention
Masking
Double (Participant, Investigator)

Eligibility Criteria

Ages
50 Years to 75 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Normal-overweight (body mass index [BMI] of 18-30 kg/m^2)
  • Women will be postmenopausal, with no menstrual period in 12 months
  • Non-smoking
  • Consume fiber intakes of less than < 20 g/d
  • White blood cell count 3,000-11,000/mm^3
  • Platelet count 100,000-400,000 mm^3
  • Hematocrit 33-50% (women); 36-50% (men)
  • Bilirubin 0.2-1.3 mg/dL
  • Aspartate aminotransferase (AST) 0-35 U/L
  • Alanine aminotransferase (ALT) 0-40 U/L
  • Alkaline phosphatase 20-125 U/L
  • Creatinine =< 1.2 mg/dL
  • Potassium 3.5-5.0 mmol/L

Exclusion Criteria

  • Chronic medical illness, history of gastrointestinal disorders (e.g., ulcerative colitis, Crohn disease, celiac sprue, hereditary nonpolyposis colorectal cancer [HNPCC], familial adenomatous polyposis, pancreatic disease, previous gastrointestinal resection, radiation or chemotherapy, and cancer (other than non-melanoma skin cancer)
  • Weight change greater than 4.5 kg within past year
  • Oral or intravenous (IV) antibiotic use within the past 3 months
  • Regular use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Smoking or use of cannabis products
  • Known allergy to fish
  • Intention to relocate out of study area within next 4 months

Outcomes

Primary Outcomes

Feasibility and Retention for a Trial With Daily Doses of 35 g of Fiber and 6.2 g of EPA +DHA (and Corresponding Comparators)

Time Frame: Baseline to completion of the 2 study time periods

This grant is an R21 with the intent to provide preliminary data to propose a trial with a larger sample size and adequate statistical power.

Secondary Outcomes

  • Number of Differentially Expressed Exfoliome Genes at p<0.01(End of Fiber Plus Fish Oil Supplementation vs end of Comparator)
  • Compliance(Average at the end of each intervention period)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Johanna Lampe

Professor

Fred Hutchinson Cancer Center

Study Sites (2)

Loading locations...

Similar Trials